Genfit (NASDAQ:GNFT) Shares Down 2%

Genfit S.A. (NASDAQ:GNFT)’s share price fell 2% on Tuesday . The stock traded as low as $3.97 and last traded at $4.02. 995 shares changed hands during trading, a decline of 94% from the average session volume of 16,338 shares. The stock had previously closed at $4.10.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $13.00 price objective on shares of Genfit in a report on Monday, July 29th.

Genfit Price Performance

The company has a current ratio of 2.94, a quick ratio of 2.94 and a debt-to-equity ratio of 0.92. The firm’s 50-day simple moving average is $4.23 and its 200 day simple moving average is $4.02.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Genfit stock. Optiver Holding B.V. increased its holdings in shares of Genfit S.A. (NASDAQ:GNFT) by 2,229.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 82,359 shares of the company’s stock after purchasing an additional 78,823 shares during the period. Optiver Holding B.V. owned approximately 0.17% of Genfit worth $315,000 at the end of the most recent quarter. Institutional investors own 2.24% of the company’s stock.

Genfit Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.